Publish to Newswire
Add an EventFrom the Open-Publishing Calendar
From the Open-Publishing Newswire
Indybay Feature
To SEC:Did Judge Ken Reilly & attorney O'Quinn aid terrorism ?
The answer is we simply don't know but even they would have to admit
they may have if they can give no more accounting for Endovasc
Ltd.'s,(of Montgomery, Texas), unaudited shares sent to Bellador
Group's boiler room in Kuala Lumpur than their Endovasc clients have.
they may have if they can give no more accounting for Endovasc
Ltd.'s,(of Montgomery, Texas), unaudited shares sent to Bellador
Group's boiler room in Kuala Lumpur than their Endovasc clients have.
Dear SEC,
This 'article' in houston.indymedia today is based upon your own
filings with link attached.But please read and note email from Judge
Ken Reilly who denies being on Endovasc's Compensation Committee
although that is what the Endovasc filings say !!! What gives ?? Why
let this fraud go on and why let the scamsters tout unendlessly on
ragingbull and put out more fraudulent Businesswire etc. prs ?
And note also Bellador Group's Endovasc scam warning.Why was this
never investigated ?Why in this post 911 era does SEC allow what
easily is money laundering or just defrauding of investors with U.S.
penny stocks ? Why do you not stop Reg S that you know allows this ?
Who are the people in the Beltway lobbying to maintain this obvious
vehicle not only for penny stock fraud but money laundering ? I don't
get it but the corruption up there is unbelievable.And it spreads
around the world.
I will add the threats and self righteous accusations of Arizona
attorney Logan representing Bellador Group and a Mr.Taylor and their
former interest in Endovasc from offshorebusiness soon so you can see
what they said to me through offshorebusiness message board some time
back.Mr.Logan also makes fraudulent claim Endovasc is 'naked shorted
knowing full well it is the unaudited shares that SEC encourages that
allows him to make such outrageous claims as Bellador touts and dumps
them in a Kuala Lumpur or even Dubai boiler room op !! Why ???
Also the Dallas-Fort Worth office and Brent Baker knew about all this
in 2004 and covered it up.Why ?? This is the same ex-SEC attorney
Brent Baker who allowed Agora,Inc.,James Dale Davidson,and Porter
Stansberry, (who now touts for his Utah Overstock.com client)to get
away scott free. And they were using the false 'naked short' claim
for fraud to mask their illegal pump and activity that now Mr.Baker
appears to defend.Why ???!!!
And still the madness goes on and on and on.....
Sincerely
Tony Ryals
Did Judge Ken Reilly and Houston attorney O'Quinn aid terrorists ?
http://houston.indymedia.org/news/2005/09/43795.php
Did Judge Ken Reilly and Houston attorney John O'Quinn aid terrorists ?
The answer is we simply don't know but even they would have to admit
they may have if they can give no more accounting for Endovasc
Ltd.'s,(of Montgomery, Texas), unaudited shares sent to Bellador
Group's boiler room in Kuala Lumpur than their Endovasc clients have.
It is Bellador Group's Arizona attorney who 'credits'
Dwight Cantrell and Robert Johnson of Endovasc,with providing an
untold quantity of shares for distribution in this terrorist money
laundering suspect region of the world.(This from
offshorebusiness.com will be
added as additional commentary at bottom shortly.)
My previous article-complaints in houston.indymedia and other
indymedias have been met by cold silence from all parties involved.I
choose here to let my letter to Judge Ken Reilly of today and the SEC
filing in question speak for themselves with links to my previous
articles,'Has Texas attorney O'Quinn covered up stock fraud and money
laundering',as well as,'Judge Ken Reilly,Endovasc and money
laundering in Montgomery,Texas',available to all concerned at the
bottom of this release.
Immediately below,and before my most recent letter of record to the
Montgomery,Texas judge,is a link to one of the judges own
self-promoting websites.It is he,as you can see from his own
statements taken from that website,who bills himself not just as a
county judge but also as a business and corporate expert including
on,'Corporate Directorships - The responsibilities & liabilities of
corporate directors.'
And yet he has either allowed his name to be placed erroneously and
or fraudulently on an Endovasc SEC filing or has decided to deny it
in retrospect.Which is it Judge Ken Reilly ?You can't have it both
ways.
And will you now deny knowing Houston's 'famed trail attorney John M.
O'Quinn' just as you deny knowing the Beltway's 'anti-naked short'
penny stock scamster James Dale Davidson who illegally touted or
promoted then dumped his Endovasc shares on defrauded victims ? Does
attorney O'Quinn deny knowing James Dale Davidson ? (Do a 'naanss
davidson clinton' google search for bits of that story.)
http://www.kenreilly.com/
Looking for a speaker at your next corporate meeting, conference,
retreat, or convention?
LOOK NO MORE!!!
KEN REILLY
(NATIONAL SPEAKERS ASSOCIATION - Professional Member)
With over 41 years of professional speaking experience, Hon. Ken
Reilly is the perfect presenter for your next event!
Learn More About Ken Reilly
Ken is now accepting speaking engagements for corporate and
association events. His presentations include the following:
Keynotes
Environmental Responsibility - The economic benefits of producing
environmentally-friendly products
Corporate Directorships - The responsibilities & liabilities of
corporate directors
Business Ethics - Public and corporate expectations in the post-Enron era
The History of Golf - A keynote speech for corporate/association
golf-related hospitality events
September 20,2005
Dear Judge Ken Reilly,
I have contemplated this portion of the SEC filing below regarding
your appointment to the Endovasc Compensation Committee for some time
since our last brief communication in 2004 in which you claimed to be
helping me get to the truth re Endovasc and my loss of 100% of my
investment. Below you will find your correspondence to me.
Also you will find the link to the 10QSB of 2003 announcing that, 'on
September 21, 2002, the Board considered the appointments of an Audit
and Compensation Committee. The Board unanimously appointed Judge Ken
Reilly as Chairman of the Compensation Advisory Board...' So I am
asking simply, is this true or is the SEC filing in error ?
I am in the process of putting some writing together not only on the
fraudulent claim made by David P Summers and attorney O'Quinn re
naked shorting that I believe was used to divert attention from
illegal pumps and dumps by Endovasc and the approval by Dwight
Cantrell of a Schwab account of 'up to 30 million shares' in May
2002, even before the fraudulent 'reverse split' that should have
left under 3 million shares in July,but also a boiler room deal with
Bellador Group of Kuala Lumpur that also has ties to Dubai.Money
laundering,even for terrorist activities may have been involved.
I also have reason to believe James Dale Davidson who now appears to
have Middle East connections may have been involved in the Bellador
Group boiler room deal as well.I am almost positive he was involved
in the Schwab pump and dump account that may have been Schwab's LOM
of Bermuda account.Mr.Davidson had recommended LOM in his book,'The
Sovereign Individual',without disclosing at the time he was a
substantial share holder.
While I would appreciate any help or information you might give me
regarding these affairs I particularly wish an answer as to whether
the SEC filing was correct or in error regarding your appointment to
the 'Compensation Committee.You might also do me favor and request
that Endovasc's 'management' insist insiders with aliases
diffdrummer0,meangene53,and kingorschmuck,etc.,cease and desist from
further fraudulent touting of EVSC and EVSD shares on ragingbull.com.
I am glad to quote verbatim any comments you may have re the fraud
called Endovasc of Montgomery,Texas AND YOUR ACKNOWLEDGEMENT OR
REBUTTAL ABOUT THE ACCURACY OF THE SEC FILING USING YOUR NAME.But I
am anxious to finish the article I have already begun.You may find
more re Bellador Group andan Arizona attorney named Logan who works
for them by asking Dwight Cantrell and Robert Johnson or I can give
you contact information and statements by them if you like.
Bellador Group's Mr.Taylor and Mr.Logan acknowledge having made a
deal with Cantrell and Johnson but this is not mentioned in Endovasc
SEC filings.Why ? Bellador Group has a bad reputation in Hong Kong
and citizens there have been warned to stay away by Hong Kong
government.And even Belladorgroup.com placed a 'scam warning' re
transactions involving Endovasc shares in early 2004.Were you aware
of this ?
So you see I am not only in shock at the fraud and internet
cyberfraud against me that I have literally paid for,I have rewarded
these scamsters in Montgomery,Texas for harrssing and tormenting for
years over over the internet and in being conned by a Stanford
patent,but as an American totally distaught in this post 911 era to
know that my money was used in what appears to be a money laundering
operation with unaudited U.S.penny stock shares in Kuala Lumpur with
ties to Dubai among other places.I'm sorry Robert Johnson,et.al.,
can't think of another way to get himself some 'cowboy boots'.
Sincerely,
Tony Ryals
P.S.- The reason my email account has changed and the account you are
replying to is not in my name is precisely because my biodog0 account
at Yahoo was deleted by the very penny stock mafia I am fighting
there as well.
Judge Ken Reilly personal communication from 2004:
Reillytalk (at) aol.com wrote:
Dear Mr. Ryals:
There has been a substantial amount of misinformation posted on
Raging Bull and relating to EVSC. Perhaps this response will help you
to know a bit more of the truth.
I have never been a member of the Endovasc Audit Committee or any
other Audit Committee associated with this firm or its predecessors
or affiliates.
I have never received compensation of any form for service on any
Audit Committee.
I am not now and never have been an Officer, Director or Employee of
any of said firms.
I do not know Mr. James Dale Davidson, have never met him or done any
business with him.I have no personal knowledge regarding Mr. Davidson
association with any of said firms.
I have occasionally provided Legal Counsel to Endovasc. I am unable
to share any of that information with you as you are not my client.
It is regrettable that you have suffered a financial loss due to your
investment in Endovasc;however, I am not a good source of any further
information and request that you cease and desist in your contacts
with me or published comments about me.
I have practiced my profession honorably for the past 43 years ( as
you learned in your Bar Assn search). I intend to continue to abide
by the Lawyers Cannon of Ethics.
I learned many years ago that practicing Attorneys often make good
targets for their unlicensed opponent's criticism. However, the Law
does provide adequate remedy for libelous assertions.
Mr. Ryals, you seem like an intelligent fellow. Don't minimize your
effectiveness by repeating gossip.
Respectfully yours,
Ken Reilly
tony ryals wrote:
Dear Ken Reilly,Thanks much for your reply.Had you noticed earlier
that Mr.s Cantrell and Summers were using your name on their website
to add 'credibilty to
their 'company' I am sure you would have acted sooner to inform
unwary 'investors'.
I sure wish I knew just who the insiders are who have used and use
ragingbull to promote their fraud.
Sincerely,
Tony Ryals
From 2003 SEC filing with link :
Judge Ken Reilly,Chairman of the Compensation Advisory Board
http://www.sec.gov/Archives/edgar/data/1040415/000101540203001859/0001015402-03-001859.txt
At a special meeting of the Board of Directors held on September 21,
2002, theBoard considered the appointments of an Audit and
Compensation Committee. The Board unanimously appointed Judge Ken
Reilly as Chairman of the Compensation Advisory Board and Ken Beverly
as Chairman of the Audit Advisory Committee to the Board of
Directors. Previously announced Beuttenmuller, Bagrier and Davidson,
were made prior to the Sarbanes/Oxley Act, and were rescinded by the
Board until further review by the respective Chairman. On November
18, 2002, the annual shareholders meeting took place at the Del Lago
Hotel and Resort,Montgomery, Texas, with all issues placed before the
shareholders approved for the coming year. In November and December
2002, the Company awarded contracts to two (2) certified good
manufacturing (cGMP) contract
laboratories to manufacture and validate both of the Company's
pending Phase III drugs. Upon completion and validation of each of
the drugs for FDA requirements, an initialnew drug application (IND)
will be filed with the FDA for Phase III clinical trials. As of March
31, 2003, the products have been produced and are pending
cGMP release in June 2003 for Phase III trials on Liprostin. Phase
III trials for Angiogenix are expected to commence in the quarter
ended December 31, 2003.
RESULTS OF OPERATIONS
- -----------------------
THREE MONTH PERIODS ENDED MARCH 31, 2003 AND 2002
- ---------------------------------------------------------
During the three months ended March 31, 2003, the Company had revenue
of $94,000 compared with $161,000 of revenues for the three months
ended March 31,2002. The revenue during the three months ended March
31, 2003 was a result ofrevenue received for funding its research and
development costs related to itsNicotine Receptor Agonist and stent
coating processes.
During the three months ended March 31, 2003 and 2002, administrative
andoperating expenses were $549,000 and $249,000, respectively. The
increase incosts and operating expenses is primarily due to an
increase in stock based
compensation to third party consultants during the three months ended
March 31,2003.
Research and development costs totaled $1,032,000 during the three
months ended March 31, 2003, compared to $245,000 during the three
months ended March 31, 2002. This increase of $787,000 was related to
the increased cost ofmaterials, labor and travel associated with the
preparation for Phase III clinical studies with Liprostin (TM) and
the ongoing, in-house projects for medicinally coated vascular stents
and a biodegradable resorbable stent.
Interest expense decreased from $14,000 during the three months ended
March 31, 2002 to $4,000 during the three months ended March 31,
2003. This decrease is a result of a lower average debt balance and
lower interest rates.
NINE MONTH PERIODS ENDED MARCH 31, 2003 AND 2002
- --------------------------------------------------------
During the nine months ended March 31, 2003, the Company had total
revenues of $293,000 compared with $407,000 of revenues for the nine
months ended March 31, 2002. The decrease relates to less revenue
received from an external
research agreement with another company entered into in July 2001
whereby the Company received assistance in funding its research and
development costs related to its Nicotine Receptor Agonist.
During the nine months ended March 31, 2003 and 2002, administrative
and operating expenses were $3,328,000 and $913,000, respectively.
The increase in costs and operating expenses is primarily due to an
increase in
facilities cost,personnel, including stock based compensation paid to
third party consultants
and attorneys, and overhead as rent and other costs increased.
Research and development costs totaled $2,338,000 during the nine
months ended March 31, 2003, compared to $984,000 during the nine
months ended March 31, 2002. This increase of $1,354,000 was related
to the increased cost of
materials, labor and travel related to the preparation for Phase III
clinical studies with Liprostin (TM) and the ongoing, in-house
projects for medicinally coated vascular stents and a biodegradable
resorbable stent.
Interest expense decreased from $207,000 during the nine months ended
March 31, 2002 to $51,000 during the nine months ended March 31,
2003. This decrease
is primarily a result of the cost of the beneficial conversion
feature related to the convertible debentures recorded during the
nine months ended March 31,
2002 of $171,000.
LIQUIDITY AND CAPITAL RESOURCES
- ----------------------------------
The Company had a working capital deficit at March 31, 2003 of
$(540,000), compared to a deficit of $(736,000) at December 31, 2002.
This decrease in the working capital deficit is primarily related to
the decrease in
accounts payable resulting from the issuance of common stock for
payment of accounts payable during the nine months ended March 31,
2003.
The Company requires significant additional funds to enable it to
proceed with its two Phase III Liprostin(TM) and Phase III
ANGIOGENIX(TM) clinical trials.
The Company continues to actively pursue additional
financing,collaborations with firms, and other arrangements aimed at
increasing its capital resources. Failure to acquire such funds may
adversely impact the
scheduled marked introduction of Liprostin(TM) and ANGIOGENIX(TM) and
possibly adversely affect the Company's operations. In order to
continue as a going concern, the Company must raise additional funds
and ultimately achieve profit from its operation; however, there can
be no assurance that the Company will obtain profitability or that
future debt or equity funding will be
available or have terms acceptable to the Company. These factors
raise substantial doubt as to the Company's ability to continue as a
going concern. The report of the
Company's independent public accountants, which accompanied the
financial statements for the year ended June 30, 2002, was qualified
with
respect to that risk.
CRITICAL ACCOUNTING POLICIES
- ------------------------------
RESEARCH AND DEVELOPMENT
- --------------------------
Research and development costs are expensed as incurred. These costs
consist of direct and indirect costs associated with specific
projects.
STOCK-BASED COMPENSATION
- -------------------------
Stock-based compensation is accounted for using the intrinsic value
mathod prescribed in Accounting Principles Board Opinion ("APB") No.
25, "Accounting for Stock Issued to Employees", rather than applying
the fair value method
prescribed in SFAS No. 123, "Accounting for Stock-Based Compensation".
LOSS PER SHARE
- ----------------
Basic and diluted loss per share is computed on the basis of the
weighted average number of shares of common stock outstanding during
each period. Common equivalent shares from common stock options and
warrants and Series A, B and C convertible preferred stock are
excluded from the computation as their effect would dilute the loss
per share for all periods presented.
ITEM 3. EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
- ------- -----------------------------------------------------
David P. Summers, Chief Executive Officer of the Company & M.Dwight
Cantrell, Chief Financial Officer of the Company, have concluded that
their disclosure controls and procedures are appropriate and
effective. They have
evaluated the controls and procedures as of a date within 90 days of
the filing date of this report on Form 10-QSB. There were no
significant changes in our internal controls or in other factors that
could significantly affect these
controls subsequent to the date of their evaluation, including any
corrective actions with regard to significant deficiencies and
material weaknesses.
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
- ------- ------------------
On September 11, 2002 the company filed a civil lawsuit styled
Endovasc Ltd., Inc v. J.P. Turner & Co. LLC et al, Number 02-CV-7313,
in the United States District Court, Southern District of New York.
The complaint is for
damages as a result of an alleged fraud and stock manipulation. The
company is seeking monetary damages in excess of $200,000,000. In a
related matter, a show
cause complaint was filed against the Company on September 19, 2002
styled Balmore SA etal v Endovasc Ltd., Inc. A hearing was held on
September 26, 2002 with the Judge issuing an unfavorable ruling
against the Company. The
matter was settled through the issuance of 203,000 shares of the
Company's common stock. In another related matter, a show cause
complaint was filed against the Company on October 17, 2002 styled
Laurus Master Fund Ltd. et al v Endovasc Ltd, Inc., Number 02-
CV-8317, in the United States District Court, Southern District of
New York. This suit involves the issuance of 430,476 shares of stock.
This matter was settled through the issuance of the Company's common
stock to retire Series A Preferred Convertible stock. In another
related matter the Company has become a defendant in arbitration
styled V Finance v. Endovasc Ltd., Inc. This matter relates to
performance under a Funding Agreement. The Company
intends to defend its position vigorously as it believes it will
prevail and,accordingly,has not accrued any liability associated with
this case in the accompanying
unaudited condensed financial statements.
ITEM 2. CHANGES IN SECURITIES
- ------- -----------------------
Recent Sale of Unregistered Securities. During the nine months ended
March 31, 2003, the following transactions were effected by us in
reliance upon exemptions from registration under the Securities Act
of 1933 as amended (the "Act"). Unless stated otherwise, we believe
that each of the persons who received these unregistered securities
had knowledge and experience in financial and business matters which
allowed them to evaluate the merits and risk of the receipt of these
securities, and that they were knowledgeable about our operations and
financial condition. No underwriter participated in, nor did we
pay any commissions or fees to any underwriter in connection with the
transactions. These transactions did not involve a public offering.
Each certificate issued for these unregistered securities contained a
legend stating
that the securities have not been registered under the Act and
setting forth the restrictions on the transferability and the sale of
the securities.
During the 9 month period ending March 31, 2003 we issued an
aggregate of 3,530,460 shares of common stock for services, which we
valued at prices ranging from $0.62 to $2.19 per share, with an
aggregate value of $4,060,000. These transactions were exempt from
registration pursuant to Section 4(2)
of the Act.
During the 9 month period ending March 31, 2003 we issued an
aggregate of 284,835 shares of common stock for cash at prices
ranging from $0.82 to $0.95 per share, with an aggregate value of
$266,000. These transactions were exempt
from registration pursuant to Section 4(2) of the Act.
During the 9 month period ending March 31, 2003 we issued 2,179,562
shares of common stock for exercise of warrants with an average
exercise price of $0.26 per share and $560,000 in the aggregate.
These transactions were exempt from registration pursuant to Section
4(2) of the Act.
During the 9 month period ending March 31, 2003 we issued a total
of31,542,345 shares of common stock upon the conversion of preferred
stock and dividends on preferred stock. We did not receive any
proceeds from these
transactions. These transactions were exempt from registration
pursuant to Section 4(2) of the Securities Act.
From http://www.belladorgroup.com's,(of Kuala Lumpur,Dubai,etc.), website:
Endovasc Scam Warning
Dated: Friday, 9 January, 2004
Dear Client
We have been advised that one of our long-standing Clients has been
contacted by a company called Bellador Institutional Services,
offering to purchase Endovasc shares in exchange for shares of
Advanced Micro Devices.
"Bellador Institutional Services" has no connection with our company,
and is being operated as a fraudulent scheme to lure unsuspecting
investors into wiring money to an account that has no connection with
Bellador Advisory Services (Labuan) Ltd, or Endovasc Inc.
The client received a recommendation that he should exchange stock
that he owns in Endovasc, Inc. for stock in Advanced Micro Devices, a
company that has a very strong recent trading history. The request
included a false claim that this company had inside information about
bad news that would soon be released about Endovasc which would
allegedly cause the trading price to fall. The client was offered the
opportunity to exchange shares of Advanced Micro Devices for Endovasc
shares before the release of the alleged bad news, but was told that
he would have to wire almost $7,000.00 U.S. to Union Bank of
California that would be forward to an account at FBME Limited in
Nicosia, Cyprus to complete the transaction.
This is a completely fraudulent scheme by a company that is not
connected with the real Bellador Advisory Services (Labuan) Limited.
We would never give this type of advice regarding the purchase or
sale of securities. It would be a violation of the securities laws of
the United States for us to provide information to you from insiders
at Endovasc that is not generally available to the investing public
and for you to purchase or sell stock based upon that inside
information that, when released to the public, might affect the
trading price.
This fraudulent company called Bellador Institutional Services has no
connection with Bellador Advisory Services (Labuan) Limited. The
Peter Taylor who is referenced in the communications from Bellador
Institutional Services is not the Peter Taylor who is a director of
Bellador Advisory Services (Labuan) Ltd. The money that you may be
requested to wire will almost certainly wind up in the hands of
criminals in Cyprus rather than being used to pay for shares of stock
in a public company called Advanced Micro Devices.
All communications with you by representatives of Bellador Advisory
Services (Labuan) Ltd will be from persons at our office who are
known to you. All real transactions will be confirmed by the usual
Transaction Confirmation letter with instructions for funds to be
sent only to trust accounts of Logan & Geotas, PLC., our law firm in
Phoenix, Arizona, USA. You will not receive wire transfer
instructions that show a bank outside of the United States as a final
destination. Cyprus has joined Nigeria and several former Soviet
republics as centers of Internet fraud and the recent schemes seem to
be targeting sophisticated, high networth investors.
Our Internet technology consultants confirm that we have a secure
firewall on our servers and that the confidential information about
addresses of our clients who previously purchased Endovasc stock has
not been compromised. The matter has been reported to the two banks
which were listed on the fraudulent wire transfer instructions.
We have notified Endovasc, Inc. of the attempted fraud. We have
requested (and Endovasc has agreed) that all future communications of
shareholder addresses between Endovasc and its stock transfer agent
be sent by facsimile transmission rather than by e-mail to reduce the
chance that confidential information about client addresses could be
obtained by the interception of e-mail messages.
Please advise us if you have any concerns or issues with the above
information, because we are treating this as a very serious matter
and we are also advising our Regulatory Authority LOFSA (Labuan
Offshore Financial Services Authority) in respect of this matter.
Bellador Advisory Services (Labuan) Ltd
Client Services Dept
Has Texas Attorney John O'Quinn covered up stock fraud and money laundering ?
http://cvilleindymedia.org/newswire.php?story_id=1788
Judge Ken Reilly,Endovasc and money laundering in Montgomery,Texas
http://www.ntimc.org/newswire.php?story_id=2828&topic=corporateglobalization
Charles Schwab and Share-Money Laundering
http://sfbay.indymedia.org/news/2005/06/1747107.php
This 'article' in houston.indymedia today is based upon your own
filings with link attached.But please read and note email from Judge
Ken Reilly who denies being on Endovasc's Compensation Committee
although that is what the Endovasc filings say !!! What gives ?? Why
let this fraud go on and why let the scamsters tout unendlessly on
ragingbull and put out more fraudulent Businesswire etc. prs ?
And note also Bellador Group's Endovasc scam warning.Why was this
never investigated ?Why in this post 911 era does SEC allow what
easily is money laundering or just defrauding of investors with U.S.
penny stocks ? Why do you not stop Reg S that you know allows this ?
Who are the people in the Beltway lobbying to maintain this obvious
vehicle not only for penny stock fraud but money laundering ? I don't
get it but the corruption up there is unbelievable.And it spreads
around the world.
I will add the threats and self righteous accusations of Arizona
attorney Logan representing Bellador Group and a Mr.Taylor and their
former interest in Endovasc from offshorebusiness soon so you can see
what they said to me through offshorebusiness message board some time
back.Mr.Logan also makes fraudulent claim Endovasc is 'naked shorted
knowing full well it is the unaudited shares that SEC encourages that
allows him to make such outrageous claims as Bellador touts and dumps
them in a Kuala Lumpur or even Dubai boiler room op !! Why ???
Also the Dallas-Fort Worth office and Brent Baker knew about all this
in 2004 and covered it up.Why ?? This is the same ex-SEC attorney
Brent Baker who allowed Agora,Inc.,James Dale Davidson,and Porter
Stansberry, (who now touts for his Utah Overstock.com client)to get
away scott free. And they were using the false 'naked short' claim
for fraud to mask their illegal pump and activity that now Mr.Baker
appears to defend.Why ???!!!
And still the madness goes on and on and on.....
Sincerely
Tony Ryals
Did Judge Ken Reilly and Houston attorney O'Quinn aid terrorists ?
http://houston.indymedia.org/news/2005/09/43795.php
Did Judge Ken Reilly and Houston attorney John O'Quinn aid terrorists ?
The answer is we simply don't know but even they would have to admit
they may have if they can give no more accounting for Endovasc
Ltd.'s,(of Montgomery, Texas), unaudited shares sent to Bellador
Group's boiler room in Kuala Lumpur than their Endovasc clients have.
It is Bellador Group's Arizona attorney who 'credits'
Dwight Cantrell and Robert Johnson of Endovasc,with providing an
untold quantity of shares for distribution in this terrorist money
laundering suspect region of the world.(This from
offshorebusiness.com will be
added as additional commentary at bottom shortly.)
My previous article-complaints in houston.indymedia and other
indymedias have been met by cold silence from all parties involved.I
choose here to let my letter to Judge Ken Reilly of today and the SEC
filing in question speak for themselves with links to my previous
articles,'Has Texas attorney O'Quinn covered up stock fraud and money
laundering',as well as,'Judge Ken Reilly,Endovasc and money
laundering in Montgomery,Texas',available to all concerned at the
bottom of this release.
Immediately below,and before my most recent letter of record to the
Montgomery,Texas judge,is a link to one of the judges own
self-promoting websites.It is he,as you can see from his own
statements taken from that website,who bills himself not just as a
county judge but also as a business and corporate expert including
on,'Corporate Directorships - The responsibilities & liabilities of
corporate directors.'
And yet he has either allowed his name to be placed erroneously and
or fraudulently on an Endovasc SEC filing or has decided to deny it
in retrospect.Which is it Judge Ken Reilly ?You can't have it both
ways.
And will you now deny knowing Houston's 'famed trail attorney John M.
O'Quinn' just as you deny knowing the Beltway's 'anti-naked short'
penny stock scamster James Dale Davidson who illegally touted or
promoted then dumped his Endovasc shares on defrauded victims ? Does
attorney O'Quinn deny knowing James Dale Davidson ? (Do a 'naanss
davidson clinton' google search for bits of that story.)
http://www.kenreilly.com/
Looking for a speaker at your next corporate meeting, conference,
retreat, or convention?
LOOK NO MORE!!!
KEN REILLY
(NATIONAL SPEAKERS ASSOCIATION - Professional Member)
With over 41 years of professional speaking experience, Hon. Ken
Reilly is the perfect presenter for your next event!
Learn More About Ken Reilly
Ken is now accepting speaking engagements for corporate and
association events. His presentations include the following:
Keynotes
Environmental Responsibility - The economic benefits of producing
environmentally-friendly products
Corporate Directorships - The responsibilities & liabilities of
corporate directors
Business Ethics - Public and corporate expectations in the post-Enron era
The History of Golf - A keynote speech for corporate/association
golf-related hospitality events
September 20,2005
Dear Judge Ken Reilly,
I have contemplated this portion of the SEC filing below regarding
your appointment to the Endovasc Compensation Committee for some time
since our last brief communication in 2004 in which you claimed to be
helping me get to the truth re Endovasc and my loss of 100% of my
investment. Below you will find your correspondence to me.
Also you will find the link to the 10QSB of 2003 announcing that, 'on
September 21, 2002, the Board considered the appointments of an Audit
and Compensation Committee. The Board unanimously appointed Judge Ken
Reilly as Chairman of the Compensation Advisory Board...' So I am
asking simply, is this true or is the SEC filing in error ?
I am in the process of putting some writing together not only on the
fraudulent claim made by David P Summers and attorney O'Quinn re
naked shorting that I believe was used to divert attention from
illegal pumps and dumps by Endovasc and the approval by Dwight
Cantrell of a Schwab account of 'up to 30 million shares' in May
2002, even before the fraudulent 'reverse split' that should have
left under 3 million shares in July,but also a boiler room deal with
Bellador Group of Kuala Lumpur that also has ties to Dubai.Money
laundering,even for terrorist activities may have been involved.
I also have reason to believe James Dale Davidson who now appears to
have Middle East connections may have been involved in the Bellador
Group boiler room deal as well.I am almost positive he was involved
in the Schwab pump and dump account that may have been Schwab's LOM
of Bermuda account.Mr.Davidson had recommended LOM in his book,'The
Sovereign Individual',without disclosing at the time he was a
substantial share holder.
While I would appreciate any help or information you might give me
regarding these affairs I particularly wish an answer as to whether
the SEC filing was correct or in error regarding your appointment to
the 'Compensation Committee.You might also do me favor and request
that Endovasc's 'management' insist insiders with aliases
diffdrummer0,meangene53,and kingorschmuck,etc.,cease and desist from
further fraudulent touting of EVSC and EVSD shares on ragingbull.com.
I am glad to quote verbatim any comments you may have re the fraud
called Endovasc of Montgomery,Texas AND YOUR ACKNOWLEDGEMENT OR
REBUTTAL ABOUT THE ACCURACY OF THE SEC FILING USING YOUR NAME.But I
am anxious to finish the article I have already begun.You may find
more re Bellador Group andan Arizona attorney named Logan who works
for them by asking Dwight Cantrell and Robert Johnson or I can give
you contact information and statements by them if you like.
Bellador Group's Mr.Taylor and Mr.Logan acknowledge having made a
deal with Cantrell and Johnson but this is not mentioned in Endovasc
SEC filings.Why ? Bellador Group has a bad reputation in Hong Kong
and citizens there have been warned to stay away by Hong Kong
government.And even Belladorgroup.com placed a 'scam warning' re
transactions involving Endovasc shares in early 2004.Were you aware
of this ?
So you see I am not only in shock at the fraud and internet
cyberfraud against me that I have literally paid for,I have rewarded
these scamsters in Montgomery,Texas for harrssing and tormenting for
years over over the internet and in being conned by a Stanford
patent,but as an American totally distaught in this post 911 era to
know that my money was used in what appears to be a money laundering
operation with unaudited U.S.penny stock shares in Kuala Lumpur with
ties to Dubai among other places.I'm sorry Robert Johnson,et.al.,
can't think of another way to get himself some 'cowboy boots'.
Sincerely,
Tony Ryals
P.S.- The reason my email account has changed and the account you are
replying to is not in my name is precisely because my biodog0 account
at Yahoo was deleted by the very penny stock mafia I am fighting
there as well.
Judge Ken Reilly personal communication from 2004:
Reillytalk (at) aol.com wrote:
Dear Mr. Ryals:
There has been a substantial amount of misinformation posted on
Raging Bull and relating to EVSC. Perhaps this response will help you
to know a bit more of the truth.
I have never been a member of the Endovasc Audit Committee or any
other Audit Committee associated with this firm or its predecessors
or affiliates.
I have never received compensation of any form for service on any
Audit Committee.
I am not now and never have been an Officer, Director or Employee of
any of said firms.
I do not know Mr. James Dale Davidson, have never met him or done any
business with him.I have no personal knowledge regarding Mr. Davidson
association with any of said firms.
I have occasionally provided Legal Counsel to Endovasc. I am unable
to share any of that information with you as you are not my client.
It is regrettable that you have suffered a financial loss due to your
investment in Endovasc;however, I am not a good source of any further
information and request that you cease and desist in your contacts
with me or published comments about me.
I have practiced my profession honorably for the past 43 years ( as
you learned in your Bar Assn search). I intend to continue to abide
by the Lawyers Cannon of Ethics.
I learned many years ago that practicing Attorneys often make good
targets for their unlicensed opponent's criticism. However, the Law
does provide adequate remedy for libelous assertions.
Mr. Ryals, you seem like an intelligent fellow. Don't minimize your
effectiveness by repeating gossip.
Respectfully yours,
Ken Reilly
tony ryals wrote:
Dear Ken Reilly,Thanks much for your reply.Had you noticed earlier
that Mr.s Cantrell and Summers were using your name on their website
to add 'credibilty to
their 'company' I am sure you would have acted sooner to inform
unwary 'investors'.
I sure wish I knew just who the insiders are who have used and use
ragingbull to promote their fraud.
Sincerely,
Tony Ryals
From 2003 SEC filing with link :
Judge Ken Reilly,Chairman of the Compensation Advisory Board
http://www.sec.gov/Archives/edgar/data/1040415/000101540203001859/0001015402-03-001859.txt
At a special meeting of the Board of Directors held on September 21,
2002, theBoard considered the appointments of an Audit and
Compensation Committee. The Board unanimously appointed Judge Ken
Reilly as Chairman of the Compensation Advisory Board and Ken Beverly
as Chairman of the Audit Advisory Committee to the Board of
Directors. Previously announced Beuttenmuller, Bagrier and Davidson,
were made prior to the Sarbanes/Oxley Act, and were rescinded by the
Board until further review by the respective Chairman. On November
18, 2002, the annual shareholders meeting took place at the Del Lago
Hotel and Resort,Montgomery, Texas, with all issues placed before the
shareholders approved for the coming year. In November and December
2002, the Company awarded contracts to two (2) certified good
manufacturing (cGMP) contract
laboratories to manufacture and validate both of the Company's
pending Phase III drugs. Upon completion and validation of each of
the drugs for FDA requirements, an initialnew drug application (IND)
will be filed with the FDA for Phase III clinical trials. As of March
31, 2003, the products have been produced and are pending
cGMP release in June 2003 for Phase III trials on Liprostin. Phase
III trials for Angiogenix are expected to commence in the quarter
ended December 31, 2003.
RESULTS OF OPERATIONS
- -----------------------
THREE MONTH PERIODS ENDED MARCH 31, 2003 AND 2002
- ---------------------------------------------------------
During the three months ended March 31, 2003, the Company had revenue
of $94,000 compared with $161,000 of revenues for the three months
ended March 31,2002. The revenue during the three months ended March
31, 2003 was a result ofrevenue received for funding its research and
development costs related to itsNicotine Receptor Agonist and stent
coating processes.
During the three months ended March 31, 2003 and 2002, administrative
andoperating expenses were $549,000 and $249,000, respectively. The
increase incosts and operating expenses is primarily due to an
increase in stock based
compensation to third party consultants during the three months ended
March 31,2003.
Research and development costs totaled $1,032,000 during the three
months ended March 31, 2003, compared to $245,000 during the three
months ended March 31, 2002. This increase of $787,000 was related to
the increased cost ofmaterials, labor and travel associated with the
preparation for Phase III clinical studies with Liprostin (TM) and
the ongoing, in-house projects for medicinally coated vascular stents
and a biodegradable resorbable stent.
Interest expense decreased from $14,000 during the three months ended
March 31, 2002 to $4,000 during the three months ended March 31,
2003. This decrease is a result of a lower average debt balance and
lower interest rates.
NINE MONTH PERIODS ENDED MARCH 31, 2003 AND 2002
- --------------------------------------------------------
During the nine months ended March 31, 2003, the Company had total
revenues of $293,000 compared with $407,000 of revenues for the nine
months ended March 31, 2002. The decrease relates to less revenue
received from an external
research agreement with another company entered into in July 2001
whereby the Company received assistance in funding its research and
development costs related to its Nicotine Receptor Agonist.
During the nine months ended March 31, 2003 and 2002, administrative
and operating expenses were $3,328,000 and $913,000, respectively.
The increase in costs and operating expenses is primarily due to an
increase in
facilities cost,personnel, including stock based compensation paid to
third party consultants
and attorneys, and overhead as rent and other costs increased.
Research and development costs totaled $2,338,000 during the nine
months ended March 31, 2003, compared to $984,000 during the nine
months ended March 31, 2002. This increase of $1,354,000 was related
to the increased cost of
materials, labor and travel related to the preparation for Phase III
clinical studies with Liprostin (TM) and the ongoing, in-house
projects for medicinally coated vascular stents and a biodegradable
resorbable stent.
Interest expense decreased from $207,000 during the nine months ended
March 31, 2002 to $51,000 during the nine months ended March 31,
2003. This decrease
is primarily a result of the cost of the beneficial conversion
feature related to the convertible debentures recorded during the
nine months ended March 31,
2002 of $171,000.
LIQUIDITY AND CAPITAL RESOURCES
- ----------------------------------
The Company had a working capital deficit at March 31, 2003 of
$(540,000), compared to a deficit of $(736,000) at December 31, 2002.
This decrease in the working capital deficit is primarily related to
the decrease in
accounts payable resulting from the issuance of common stock for
payment of accounts payable during the nine months ended March 31,
2003.
The Company requires significant additional funds to enable it to
proceed with its two Phase III Liprostin(TM) and Phase III
ANGIOGENIX(TM) clinical trials.
The Company continues to actively pursue additional
financing,collaborations with firms, and other arrangements aimed at
increasing its capital resources. Failure to acquire such funds may
adversely impact the
scheduled marked introduction of Liprostin(TM) and ANGIOGENIX(TM) and
possibly adversely affect the Company's operations. In order to
continue as a going concern, the Company must raise additional funds
and ultimately achieve profit from its operation; however, there can
be no assurance that the Company will obtain profitability or that
future debt or equity funding will be
available or have terms acceptable to the Company. These factors
raise substantial doubt as to the Company's ability to continue as a
going concern. The report of the
Company's independent public accountants, which accompanied the
financial statements for the year ended June 30, 2002, was qualified
with
respect to that risk.
CRITICAL ACCOUNTING POLICIES
- ------------------------------
RESEARCH AND DEVELOPMENT
- --------------------------
Research and development costs are expensed as incurred. These costs
consist of direct and indirect costs associated with specific
projects.
STOCK-BASED COMPENSATION
- -------------------------
Stock-based compensation is accounted for using the intrinsic value
mathod prescribed in Accounting Principles Board Opinion ("APB") No.
25, "Accounting for Stock Issued to Employees", rather than applying
the fair value method
prescribed in SFAS No. 123, "Accounting for Stock-Based Compensation".
LOSS PER SHARE
- ----------------
Basic and diluted loss per share is computed on the basis of the
weighted average number of shares of common stock outstanding during
each period. Common equivalent shares from common stock options and
warrants and Series A, B and C convertible preferred stock are
excluded from the computation as their effect would dilute the loss
per share for all periods presented.
ITEM 3. EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
- ------- -----------------------------------------------------
David P. Summers, Chief Executive Officer of the Company & M.Dwight
Cantrell, Chief Financial Officer of the Company, have concluded that
their disclosure controls and procedures are appropriate and
effective. They have
evaluated the controls and procedures as of a date within 90 days of
the filing date of this report on Form 10-QSB. There were no
significant changes in our internal controls or in other factors that
could significantly affect these
controls subsequent to the date of their evaluation, including any
corrective actions with regard to significant deficiencies and
material weaknesses.
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
- ------- ------------------
On September 11, 2002 the company filed a civil lawsuit styled
Endovasc Ltd., Inc v. J.P. Turner & Co. LLC et al, Number 02-CV-7313,
in the United States District Court, Southern District of New York.
The complaint is for
damages as a result of an alleged fraud and stock manipulation. The
company is seeking monetary damages in excess of $200,000,000. In a
related matter, a show
cause complaint was filed against the Company on September 19, 2002
styled Balmore SA etal v Endovasc Ltd., Inc. A hearing was held on
September 26, 2002 with the Judge issuing an unfavorable ruling
against the Company. The
matter was settled through the issuance of 203,000 shares of the
Company's common stock. In another related matter, a show cause
complaint was filed against the Company on October 17, 2002 styled
Laurus Master Fund Ltd. et al v Endovasc Ltd, Inc., Number 02-
CV-8317, in the United States District Court, Southern District of
New York. This suit involves the issuance of 430,476 shares of stock.
This matter was settled through the issuance of the Company's common
stock to retire Series A Preferred Convertible stock. In another
related matter the Company has become a defendant in arbitration
styled V Finance v. Endovasc Ltd., Inc. This matter relates to
performance under a Funding Agreement. The Company
intends to defend its position vigorously as it believes it will
prevail and,accordingly,has not accrued any liability associated with
this case in the accompanying
unaudited condensed financial statements.
ITEM 2. CHANGES IN SECURITIES
- ------- -----------------------
Recent Sale of Unregistered Securities. During the nine months ended
March 31, 2003, the following transactions were effected by us in
reliance upon exemptions from registration under the Securities Act
of 1933 as amended (the "Act"). Unless stated otherwise, we believe
that each of the persons who received these unregistered securities
had knowledge and experience in financial and business matters which
allowed them to evaluate the merits and risk of the receipt of these
securities, and that they were knowledgeable about our operations and
financial condition. No underwriter participated in, nor did we
pay any commissions or fees to any underwriter in connection with the
transactions. These transactions did not involve a public offering.
Each certificate issued for these unregistered securities contained a
legend stating
that the securities have not been registered under the Act and
setting forth the restrictions on the transferability and the sale of
the securities.
During the 9 month period ending March 31, 2003 we issued an
aggregate of 3,530,460 shares of common stock for services, which we
valued at prices ranging from $0.62 to $2.19 per share, with an
aggregate value of $4,060,000. These transactions were exempt from
registration pursuant to Section 4(2)
of the Act.
During the 9 month period ending March 31, 2003 we issued an
aggregate of 284,835 shares of common stock for cash at prices
ranging from $0.82 to $0.95 per share, with an aggregate value of
$266,000. These transactions were exempt
from registration pursuant to Section 4(2) of the Act.
During the 9 month period ending March 31, 2003 we issued 2,179,562
shares of common stock for exercise of warrants with an average
exercise price of $0.26 per share and $560,000 in the aggregate.
These transactions were exempt from registration pursuant to Section
4(2) of the Act.
During the 9 month period ending March 31, 2003 we issued a total
of31,542,345 shares of common stock upon the conversion of preferred
stock and dividends on preferred stock. We did not receive any
proceeds from these
transactions. These transactions were exempt from registration
pursuant to Section 4(2) of the Securities Act.
From http://www.belladorgroup.com's,(of Kuala Lumpur,Dubai,etc.), website:
Endovasc Scam Warning
Dated: Friday, 9 January, 2004
Dear Client
We have been advised that one of our long-standing Clients has been
contacted by a company called Bellador Institutional Services,
offering to purchase Endovasc shares in exchange for shares of
Advanced Micro Devices.
"Bellador Institutional Services" has no connection with our company,
and is being operated as a fraudulent scheme to lure unsuspecting
investors into wiring money to an account that has no connection with
Bellador Advisory Services (Labuan) Ltd, or Endovasc Inc.
The client received a recommendation that he should exchange stock
that he owns in Endovasc, Inc. for stock in Advanced Micro Devices, a
company that has a very strong recent trading history. The request
included a false claim that this company had inside information about
bad news that would soon be released about Endovasc which would
allegedly cause the trading price to fall. The client was offered the
opportunity to exchange shares of Advanced Micro Devices for Endovasc
shares before the release of the alleged bad news, but was told that
he would have to wire almost $7,000.00 U.S. to Union Bank of
California that would be forward to an account at FBME Limited in
Nicosia, Cyprus to complete the transaction.
This is a completely fraudulent scheme by a company that is not
connected with the real Bellador Advisory Services (Labuan) Limited.
We would never give this type of advice regarding the purchase or
sale of securities. It would be a violation of the securities laws of
the United States for us to provide information to you from insiders
at Endovasc that is not generally available to the investing public
and for you to purchase or sell stock based upon that inside
information that, when released to the public, might affect the
trading price.
This fraudulent company called Bellador Institutional Services has no
connection with Bellador Advisory Services (Labuan) Limited. The
Peter Taylor who is referenced in the communications from Bellador
Institutional Services is not the Peter Taylor who is a director of
Bellador Advisory Services (Labuan) Ltd. The money that you may be
requested to wire will almost certainly wind up in the hands of
criminals in Cyprus rather than being used to pay for shares of stock
in a public company called Advanced Micro Devices.
All communications with you by representatives of Bellador Advisory
Services (Labuan) Ltd will be from persons at our office who are
known to you. All real transactions will be confirmed by the usual
Transaction Confirmation letter with instructions for funds to be
sent only to trust accounts of Logan & Geotas, PLC., our law firm in
Phoenix, Arizona, USA. You will not receive wire transfer
instructions that show a bank outside of the United States as a final
destination. Cyprus has joined Nigeria and several former Soviet
republics as centers of Internet fraud and the recent schemes seem to
be targeting sophisticated, high networth investors.
Our Internet technology consultants confirm that we have a secure
firewall on our servers and that the confidential information about
addresses of our clients who previously purchased Endovasc stock has
not been compromised. The matter has been reported to the two banks
which were listed on the fraudulent wire transfer instructions.
We have notified Endovasc, Inc. of the attempted fraud. We have
requested (and Endovasc has agreed) that all future communications of
shareholder addresses between Endovasc and its stock transfer agent
be sent by facsimile transmission rather than by e-mail to reduce the
chance that confidential information about client addresses could be
obtained by the interception of e-mail messages.
Please advise us if you have any concerns or issues with the above
information, because we are treating this as a very serious matter
and we are also advising our Regulatory Authority LOFSA (Labuan
Offshore Financial Services Authority) in respect of this matter.
Bellador Advisory Services (Labuan) Ltd
Client Services Dept
Has Texas Attorney John O'Quinn covered up stock fraud and money laundering ?
http://cvilleindymedia.org/newswire.php?story_id=1788
Judge Ken Reilly,Endovasc and money laundering in Montgomery,Texas
http://www.ntimc.org/newswire.php?story_id=2828&topic=corporateglobalization
Charles Schwab and Share-Money Laundering
http://sfbay.indymedia.org/news/2005/06/1747107.php
We are 100% volunteer and depend on your participation to sustain our efforts!
Donate
$230.00 donated
in the past month
Get Involved
If you'd like to help with maintaining or developing the website, contact us.
Publish
Publish your stories and upcoming events on Indybay.
Topics
More
Search Indybay's Archives
Advanced Search
►
▼
IMC Network
http://www.offshorebusiness.com/message_board.asp
by Ron Logan the Arizona attorney for the Bellador Group boiler room ops located in Kuala Lumpur and Dubai, etc. These types of questionable penny stock operators are allowed to deal in U.S.penny stocks to the detriment of U.S. and other retail investors and shares are not generally audited by the SEC that looks the other way.
Note that Bellador's Arizona attorney Logan lauds the corrupt even criminal management of Mr.Cantrell and Mr.Johnson of Endovasc in Montgomery, Texas and has the nerve to claim the company is being 'naked shorted',meaning non-existent shares are being dumped by some unnamed party or broker.
'Bellador has been a strong supporter of the efforts of Endovasc to fight the naked shorting.'
- Belladorgroup.com Attorney Ron Logan
The sad truth is that Endovasc,Bellador Group and the corrupt Nevada Agency and Trust Company of former SEC employee Alexander Walker all worked togather to conceal the 'float' or number of shares available to be bought and sold as they themselves promoted the company with press releases etc.and all dumped or sold shares in collusion
while hiding this fact from retail investors.
Which is to say those who bought at market price from brokers such as Schwab Capital,Ameritrade,etc.No retail investor had a chance to compete with their free shares or to even know they were dumping millions even tens of millions of new shares while fraudulently claiming brokers like Charles Schwab were 'naked shorting' their company's stock as an excuse to justify the collapse of share price and thus loss of retail investors money as shares become worthless !!!
Besides defrauding naive,unsophisticated investors,including myself,this is also a conduit for laundering money and the SEC and U.S.government continue to let the fraud go on.Even Ollie North used and bought and sold penny stocks during the Iran-Contra days.Could it be that certain levels of our own government know the are rewarding and aiding an international mafia who deal with and launder with these U.S.penny stock shares ? Certainly the SEC and U.S.
ONGRESS IS NOT THAT NAIVE.
Very thoughtful business writers have brought this up,particularly Christopher Byron of Rupert Murdoch's N.Y.Post.But on the other hand Murdoch's former employee
from London Financial Times,the Lord Rees-Mogg,has been
connected to the National Taxpayers Union founder James Dale Davidson.
Both Davidson and Reees-Mogg been investors with LOM of Bermuda that has attracted attention from the SEC for huge penny stock frauds.They both recommended it for offshore investing in their book,The Sovereign Individual',without disclosing their substantial interest. And recently it has come to light that Mr.Davidson, friend to Steve Forbes and other far right Beltway insiders, has Middle East and Dubai business and no doubt U.S.penny stock deals as well.
Further Mr.James Dale Davidson,who likes to hide behind a pseudo patriotism,is founder of 'NAANSS' ,or 'National Association Against Naked Short Selling',a fraudulent website since closed down, to promote the very scam I have tried to explain above to pump and dump penny stocks and possibly launder money.And I suspect he was behind an ad
paid for by Patrick Byrne of Overstock.com and anonymous group called http://www.ncans.net headed by an unidentified individidual using pseudonym 'Bob O'Brien'.Links at bottom to stories on 'James Angel,Georgetown aids penny sock fraud' and Senator Bennett,penny stock scam,Cheetah Club' discuss that group and the ad-letter to President Bush et.al.placed in the Washington Post on February 8 claiming 'naked shorting' a serious threat to investing in the markets.
In my case with,Endovasc,I'm sorry to say even Stanford University was in on and benfitted from the fraud.The patent
promoted by Endovasc to lure investors such as myself came from Stanford which inspird confidence in the company at least in my case.Stanford as well as two professors Heeschen and Cooke mde out like bandits from a 'nicotine patent' promoted as a breakthrough discovery to induce angiogenesis or blood vessel growth.Only recently did the scandal and my complaints become enough for Stanford to withdraw their patent,too late to avoid massive stock fraud by
the ongoing 'biotech' scam called Endovasc in Montgomery, Texas and incorporated in Nevada whose corporate laws attract this paricular form of crime.
.....................................................................................
'Bellador has been a strong supporter of the efforts of Endovasc to fight the naked shorting.'
Bellador attorney Ron Logan
http://www.offshorebusiness.com/message_board_detail.asp?id=14062&page=4
Reply Re: Bellador boiler room, Endovasc,Advanced Micro Devices,etc.
By Ron Logan on 11/10/2004 4:06:36 AM
E-mail: logan [at] logan-geotas.com
Sir:
It is always troubling when anonymous, uninformed, message board "experts" make posts such as the following:
"The question remains as to why James Dale Davidson who founded 'naanss' supposedly to 'stop naked short selling' with convicted Canadian securities fraudster Brent Pierce,and who must have dumped many unaccounted for shares when he pumped through his 'Vantage Point' etc. wasn't included in this group of insider share dumpers.Nor Belladorgroup boiler room boys out of Kuala Lumpur for that matter."
I have no connection with, or special knowledge of, the other parties that you mention, but I am well informed about Bellador Advisory Services (Labuan) Limited and its operations. You are completely wrong about your accusations of short selling and regarding your claim that Bellador operates a boiler room. Your post suggests that you are do not understand what an insider is, what a boiler room is and what constitutes commercial defamation.
1. Bellador Advisory Services (Labuan) Limited owns no shares in Endovasc, Inc.
2. Bellador Advisory Services (Labuan) Limited is not a boiler room. It is a research firm and financial advisor that screens well over 60 public companies for each one that it recommends to its high net worth clients around the globe. It has an extensive due diligence system that identifies late development stage and early revenue stage companies that are expected to become highly profitable. Bellador looks for companies that occupy a unique place in their industry, have strong intellectual property protection on exciting products, can become very successful with a modest amount of capital and that have a strong management team which has a strong plan for success.
Endovasc is one of those companies. The screening, information gathering and analysis performed by Bellador's due diligence team is followed by the preparation of a report on each opportunity that is more extensive in some respects than analyst reports that are produced by major brokerage houses. Bellador, in addition to conducting research to fully understand a funding candidate's industry, undertakes careful financial due diligence, conducts extensive interviews of all key employees, examines all important contracts to which the company has entered into and requires contract terms that allow for careful monitoring of the use of proceeds. Your complete misunderstanding of Bellador brings your own credibility into question.
3. Bellador's directors, not the company itself, have invested in some companies funded by its clients, but neither Bellador nor its directors have ever sold, shorted or otherwise engaged in hedging transactions involving a single share of any funded company. Bellador is subject to exhaustive audits by the licensing authority in Labuan, the Federal Territory of Malaysia (a growing financial center in East Malaysia). Any interested party can contact the Labuan Offshore Financial Services Authority (LOFSA) and will find that Bellador Advisory Services is licensed as a fund manager and advisor and has been thoroughly audited by both LOFSA and by the Malaysia Securities Commission within the past year. The audit is intended to assure that Bellador has complied fully with the strict laws of LOFSA. Bellador is in full compliance with all applicable laws and regulations. The regulatory authorities in the Federal Territory of Labuan and in Malaysia are very aggressive in their protection of investors and not at all like the fast and loose jurisdictions that have developed reputations as havens for shady operators.
4. It is patently ridiculous to assert that Bellador would sabotage its own business by causing harm to the share price of Endovasc, Inc. or any other company that it recommends to its clients. Only if Bellador's clients experience consistently good returns will the clients have confidence in Bellador's recommendations. Bellador has an outstanding track record of recommending companies that have experienced success. Not all excellent investment opportunities bear fruit in the first year. Endovasc, for example, was viewed as a 2-3 year opportunity. Bellador has sophisticated clients and it maintains the confidence of those clients, who understand that strong companies can be shorted and that the best remedy is for the company to pursue an unwavering, determined strategy of producing good results.
Bellador has been a strong supporter of the efforts of Endovasc to fight the naked shorting. Anyone who doubts this can call Endovasc and speak with CFO Dwight Cantrell or Vice President for Business Development, Rob Johnson, about their high regard for Bellador and its directors. Mr. Cantrell and Mr. Johnson work with the attorneys for Endovasc in monitoring the naked short selling. They know who is doing it and when it is happening. They absolutely know that Bellador and its clients are a friendly ally and are not part of the problem.
Anyone who doubts the positive direction in which Endovasc is moving and the level of confidence that its investors have in the company should read the press releases linked below. Endovasc has recently reorganized as a Business Development Company and has announced the raise of $5,000,000:
http://biz.yahoo.com/bw/041007/75356_1.html
http://biz.yahoo.com/bw/041007/75357_1.html
Your delight in attacking responsible people and companies and indiscriminately lumping them into a category with bad actors is a destructive way for someone to spend their time on the Internet. You carefully hide behind the anonymity of the Internet. I have no need to do so.
Ronald J. Logan
Logan & Geotas, PLC
Attorneys at Law
Suite 300
2198 E Camelback Rd.
Phoenix, AZ 85016-4747
Office: (602) 957-9320
Internet Fax: (602) 532-7694
Below is an offshorebusiness.com message board post from Peter Taylor of Bellador Group. I mentioned in my original story above that someone coincidentally using the Bellador name as well as his own name coincidentally had been running a stock swap scam between a California bank stretching all the way to Nicosia.Note neither he nor Endovasc's Cantrell ever explain where all those unaudited Envasc shares that are supposed to be traded for AMD shares plus thousands of dollars wired to Nicosia from the California bank came from.But I doubt seriously they were non-existent 'naked shorts'.
Note how he uses the message board, much to David Marchant of offshorebusiness' disapproval, for promotion of his scam.
http://www.offshorebusiness.com/message_board_detail.asp?id=14059&page=4
Bellador Success
By Peter Taylor on 11/10/2004 2:41:34 AM
E-mail: petertaylor [at] belladorgroup.com
http://www.belladorgroup.com
After the fantastic success of Biophan last year where clients made 233% Bellador seamingly are doing it again with the most recent recommendation American Soyl Technologies SOYL in the last quarter rising 93.24%
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan product lines include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors have 21 issued U.S. patents and 71 patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life.
About American Soil Technologies Inc.
American Soil Technologies develops, manufactures and markets cutting-edge technology that decreases the need for water in agriculture and other plant growing environments while increasing crop yield and reducing the environmental damage caused by common farming practices. The company has an exclusive license to two method patents with cross-linked and linear polymers as their basis. The company also has three patents allowed on a revolutionary new machine, the M-216 Polymer Injector, designed to install its liquid products in mature turf as well as some standing crops. The machine has been built, tested and is now operational.
About Bellador:
Bellador Group carries out substantial investigation of the NASDAQ, OTC:BB and IPO markets to filter out those undervalued situations which demonstrate future potential in their given market sector. We source small and micro cap situations, which are currently under followed.
To find about more about the Bellador Group and the service we provide please visit our website at http://www.belladorgroup.com
To SEC : James Angel,Georgetown University,Aids Penny Stock Fraud
http://cvilleindymedia.org/newswire.php?story_id=1800
Senator Bennett,penny stock scam,Cheetah Club
http://sandiego.indymedia.org/en/2005/07/110190.shtml
Further reading re Bellador Group can be found at link below to the http://www.offshorebusiness.com message board.Two recent comments from that board by myself and the alias 'Mlyons' who commented to my article on austin.inymedia as well in order to put lipstick on the pig Endovasc of Montgomery, Texas and its pimp BELLADOR GROUP are also below.
THEY MAY WELL BE AIDING MONEY LAUNDERING WITH UNAUDITED U.S. PENNY STOCKS SUCH AS ATTORNEY JOHN O'QUINN'S AND JUDGE KEN REILLY'S ENDOVASC CLIENTS OF MONTGOMERY,TEXAS.OBVIOUSLY THEY DON'T WANT SHARES AUDITED BECAUSE THIS WOULD HELP IN AUDITING THE FLOW OF MONEY IN THE TERRORIST MONEY LAUNDERING FINANCIAL CENTERS IN WHICH THEY COINCIDENTALLY OPERATE.
Bellador Group,Dubai share-money laundering and Endovasc :
http://www.offshorebusiness.com/message_board.asp?search=bellador&submit=Search+text+from+messages/replies
Re: Are Davidson,Lochrie,and Amenni connected to Bellador Group ?
By MLyons on 9/24/2005 5:10:16 PM
E-mail: MLy (at) aol.com
Craig Dean works in Bellador's Dubai office as an advisor. As I indicated in a reply to another of your posts, Bellador is not the boiler-room operation you allege. Davidson, Lochrie, and Amenni have no connection to Bellador. I have personally confirmed this with them.
I'm all for chat and message boards, but the unfortunate aspect about them is that they aren't subject to any editorial process whatsoever. People are free to post false allegations, innuendo, and inaccurate information no matter what their motive, and their posts are not subject to any vetting at all. Endovasc is not performing well and I am as troubled by this as you, but to make false allegations and mislead readers/investors puts you in the company of those individuals you suggest have engaged in other wrongdoing.
Re: Is The DILIGIZER Board Up ?
By To Mr.Mlyons re Bellador - Davidson on 9/24/2005 9:53:11 PM
E-mail: endoscam (at) lycos.com
Well as one who is merely a client you seem to know a lot.You might also note I often post with questions but provide certain
facts to justify my asking them.Yes interesting James Dale Davidson has a Dubai connection through Amenni anyway,isn't it ? Maybe you through your connections at Belllador might even be able to inform us where the Amenni office is located in Dubai.Is it far from the Bellador Group office ?
And it is also at least interesting he had an Endovasc connection just before or possibly at the same time that Bellador Group did.If you all didn't cross paths,why,I'm sorry to say,you just missed him.A real pleasant fellow I'm sure.
And in fact, through Agora, a Southeast Asian connection and publication there as well I believe.David Marchant might know more about that,I'm not sure.He also has British connections as Mr.Taylor might know,having gone to Oxford and being a chum of the Lord Rees-Mogg.
Now I don't know if you are an American or not but in this post 911 era,all personal interest aside,wouldn't you have to admit,Reg S shares or any other form of shares would have to be audited or one could never guarantee,however principled the holders might be,that no money was laundered using those shares ? So getting above the fact that Mr.Cantrell and Mr.Johnson ripped me off of 100% of my investment by dumping shares through Charles Schwab and probably LOM of Bermuda and
by whatever means and route through vFinance and then on to Kuala Lumpur and maybe Nicosia for all I know by someone named or claiming to be named,coincidentally,'Mr.Taylor' of Bellador something or other......regardless of all that don't you think Bellador Group should simply disclose how much was paid for how many Endovasc shares as an example of how above board they are,and we should all be,in this post 911 era ?
And until that is done how can attorney O'Quinn of Texas or Ron Logan of Arizona dare defend Endovasc and Dwight Cantrell and Robert Johnson et.al. of being victims of naked shorting
when they apparently are pocketing a fair amount of cash of Bellador Group and or its clients as well as from James Dale Davidson and holders of that 'select clients' account and never declaring ?!!
This you see is what I call 'share-money laundering' and I have every reason to be indignant don't you think,both as an American and as a defrauded investor ? Just curious...do you believe money has ever been laundered in say,Kuala Lumpur or Dubai,with unaudited U.S.penny stock shares ?
Re: Are Davidson,Lochrie,and Amenni connected to Bellador Group ?
By MLyons on 9/24/2005 5:10:16 PM
E-mail: MLy (at) aol.com
Craig Dean works in Bellador's Dubai office as an advisor. As I indicated in a reply to another of your posts, Bellador is not the boiler-room operation you allege. Davidson, Lochrie, and Amenni have no connection to Bellador. I have personally confirmed this with them.
I'm all for chat and message boards, but the unfortunate aspect about them is that they aren't subject to any editorial process whatsoever. People are free to post false allegations, innuendo, and inaccurate information no matter what their motive, and their posts are not subject to any vetting at all. Endovasc is not performing well and I am as troubled by this as you, but to make false allegations and mislead readers/investors puts you in the company of those individuals you suggest have engaged in other wrongdoing.
Read 32 objects from the database. Queried the database 19 times. Served 1 files from the cache.